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Abstract
Background: One typical feature in chronic obstructive pulmonary disease (COPD) is the
disturbance of the oxidant/antioxidant balance. Glutaredoxins (Grx) are thiol disulfide oxido-
reductases with antioxidant capacity and catalytic functions closely associated with glutathione, the
major small molecular weight antioxidant of human lung. However, the role of Grxs in smoking
related diseases is unclear.
Methods: Immunohistochemical and Western blot analyses were conducted with lung specimens
(n = 45 and n = 32, respectively) and induced sputum (n = 50) of healthy non-smokers and smokers
without COPD and at different stages of COPD.
Results: Grx1 was expressed mainly in alveolar macrophages. The percentage of Grx1 positive
macrophages was significantly lower in GOLD stage IV COPD than in healthy smokers (p = 0.021)
and the level of Grx1 in total lung homogenate decreased both in stage I–II (p = 0.045) and stage
IV COPD (p = 0.022). The percentage of Grx1 positive macrophages correlated with the lung
function parameters (FEV1, r = 0.45, p = 0.008; FEV1%, r = 0.46, p = 0.007, FEV/FVC%, r = 0.55, p
= 0.001). Grx1 could also be detected in sputum supernatants, the levels being increased in the
supernatants from acute exacerbations of COPD compared to non-smokers (p = 0.013) and
smokers (p = 0.051).
Conclusion: The present cross-sectional study showed that Grx1 was expressed mainly in
alveolar macrophages, the levels being decreased in COPD patients. In addition, the results also
demonstrated the presence of Grx1 in extracellular fluids including sputum supernatants. Overall,
the present study suggests that Grx1 is a potential redox modulatory protein regulating the
intracellular as well as extracellular homeostasis of glutathionylated proteins and GSH in human
lung.
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The pathogenesis of chronic obstructive pulmonary dis-
ease (COPD) is probably strongly associated with reactive
oxygen metabolites. Cigarette smoke not only contains
high levels of oxidants, but it also leads to the accumula-
tion of neutrophils and macrophages in the lung and to
their activation [1-3]. A number of studies have investi-
gated antioxidant defense mechanisms in cigarette smoke
exposed cells and in chronic cigarette smokers. These
studies have found that glutathione (GSH), a thiol con-
taining tripeptide present in the epithelial lining fluid
(ELF) at high concentrations, plays an essential role in
protecting human airways against exogenous and endog-
enous oxidants and cigarette smoke [1,4,5]. However,
only some of the enzyme systems participating in GSH
regulation, and thereby probably also participating in
COPD pathogenesis, have been investigated in human
lung.
Glutathione is present in increased concentrations in the
ELF of chronic smokers [6] and both acute and chronic
exposure of experimental animals to cigarette smoke
causes depletion in the intracellular GSH concentration
[7]. GSH is transported from cells by multiple mecha-
nisms, while the plasma membrane is impermeable to
GSH preventing its transportation back into cells. The
replenishment of intracellular GSH is accomplished by
the reduction of oxidized glutathione, i.e. glutathione
disulphide (GSSG), release of GSH from the proteins and
de novo GSH synthesis [8]. Enzyme mechanisms that are
known to regulate GSH metabolism include the rate-lim-
iting enzyme in GSH synthesis, glutamate cysteine ligase
(GCL, also known as γ-glutamylcysteine synthetase, γ-
GCS), glutathione peroxidases (GPx), glutathione reduct-
ase (GR), γ-glutamyltranspeptidase (γ-GT) and glutath-
ione-S-transferases (GST). There appears to be increased
mRNA expression of GCL, GPxs and some GSTs in the
bronchial epithelium of chronic smokers, but decreased
immunoreactivities or activities of several of these
enzymes in cigarette smokers or during COPD progres-
sion [9]. Glutaredoxins (Grx) represent a redox modula-
tory protein family with potential effects on GSH
regulation and homeostasis, but until now they have not
been assessed in smoking related lung diseases.
Classical glutaredoxins are small thiol disulfide oxidore-
ductases with a conserved active site sequence -CXXC- and
a GSH binding site. They belong to the thioredoxin fold
superfamily [10,11], thioredoxin being a known redox
modulatory enzyme in human lung [12,13]. There are
two Grxs in humans, cytosolic Grx1 and mitochondrial
Grx2 [14,15]. They catalyze disulfide reductions, prefer-
ring GSH-mixed disulfides as substrates, by utilizing the
reducing power of GSH in the presence of NADPH and
glutathione reductase [16]. Grxs can be hypothesized to
participate in the reduction of the GSH-mixed disulfides
of thiol-containing proteins back to their active forms dur-
ing and after oxidative stress in cigarette smokers and in
COPD.
In this study the expression of Grxs was investigated in
lung specimens of non-smokers and cigarette smokers
and in different stages [17] of COPD or emphysema/
COPD associated with α-1-antitrypsin deficiency (GOLD
stages I, II and IV). The major focus was on macrophages,
as Grx1 is mainly expressed in these cells [18] and since
one typical feature in COPD is the accumulation of mac-
rophages in the lung. Given that Grx1 may be present also
in the extracellular space [19,20], levels of Grx1 were also
examined from induced sputum specimens, both cells




The tissue material included uninvolved peripheral lung
tissue from lung surgery (hamartomas, carcinoid tumors,
lung carcinomas) representing healthy lung from non-
smokers, smokers without COPD and stage I–II COPD
(Department of Pathology, Oulu University Hospital).
The specimens from patients with very severe COPD or
emphysema from α-1-antitrypsin deficiency (stage IV)
were retrieved from lung transplantations (Department of
Pathology, Helsinki University Hospital). The tissue mate-
rial for immunohistochemistry was preserved as described
by Dail and Hammar [21]. More detailed description can
be found from the accompanying data supplement [see
Additional file 1]. The tissue material for the Western
analysis was immediately frozen in liquid nitrogen and
stored in -80°C. Patient characteristics for specimens con-
taining separate subjects used in immunohistochemistry
(n = 44) and in Western blotting (n = 32) are shown in
Table 1 and Table 2, respectively.
Sputum induction and processing
A standard procedure for sputum induction was con-
ducted using 4.5% hypertonic saline given at 5-minute
intervals for a maximum of 20 minutes according to the
guidelines of the European Respiratory Society's Task
Force [22]. Details are described in the data supplement
[see Additional file 1]. The sputum specimens were imme-
diately centrifuged, frozen and stored at -80°C. The char-
acteristics of the patients selected for studies on induced
sputum specimens (n = 50) are shown in Table 3. The sub-
jects included non-smokers, healthy smokers and mild
stable COPD (stage 0–I) and, for comparison, cases with
more severe disease and hospitalization due to COPD
exacerbations (COPD exa). The patients did not suffer
from other diseases or pneumonia. All samples from
patients with COPD exacerbation were collected withinPage 2 of 11
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St George's Respiratory Questionnaire.
Immunohistochemistry and assessment of Grx1 in the lung
The preparation and staining protocol for paraffin sec-
tions using polyclonal goat anti-human Grx1 antibody
[19] has been described earlier [18,23]. More detailed
description is provided in the data supplement [see Addi-
tional file 1]. The immunohistochemical staining intensi-
ties were assessed semiquantitatively from ten
microscopic fields by two investigators by grading the
staining intensity from negative (0) to strong (3). In addi-
tion, at least ten microscopic fields were evaluated by cal-
culating the absolute numbers of Grx1 positive and
negative macrophages with the Zeiss AxioHOME Mor-
phometry program (Zeiss, Jena, Germany).
Western blot analyses
Frozen tissue samples were quickly homogenized in ice
cold phosphate buffered saline. Western blot analyses
from tissue homogenates and sputum specimens were
conducted as described earlier [18,23] with antibodies
against Grx1 [19] and Grx2 [15]. A more detailed descrip-
tion of the method can be found in the data supplement
[see Additional file 1]. β-Actin was not used as a loading
control for tissue homogenates since it showed high indi-
vidual variability as has been shown earlier [24,25].
Instead, the protein concentration was measured carefully
as triplicates from a set of samples and equal loading was
ensured by staining the blotted membranes with Ponceau
S (Sigma Aldrich, St. Louis, MO, USA).
Ethical considerations
The study protocol was accepted by the ethical commit-
tees of Oulu University Hospital and Helsinki University
Hospital and it is in accordance with the ethical standards
of the Helsinki declaration of 1975. The study was regis-
tered by the Helsinki University Hospital [26].
Statistics
Statistical analyses were performed with the Statistical
Package for Social Studies (SPSS) version 11.5 (Chicago,
IL, USA). Differences between controls and selected dis-
eases were compared using analysis of variance and post
Table 1: Clinical characteristics of the patients in immunohistochemistry analyses
Non-smokers Smokers COPD st I–II COPD st IV p-value
Total (n) 9 10 10 16
Male/Female 2/7 9/1 7/3 10/6
Age (years) 66 (13) 62 (7) 60 (8) 54 (7)
Pack years 0 51 (11) 32 (18) 29 (17) p < 0.0001
FEV1 (l) 2.7 (1.4) 3.0 (0.8) 2.4 (0.8) 0.6 (0.3) p < 0.0001
FEV1 (% of ref) 104 (16) 85 (10) 73 (13) 20 (10) p < 0.0001
FEV1/FVC (%) 85 (10) 79 (7) 70 (12) 34 (9) p < 0.0001
DCO (% of ref) 91 (18) 79 (15) 69 (13) 25 (8) p < 0.0001
DCO/VA (% of ref) 90 (12) 83 (12) 71 (14) 37 (10) p < 0.0001
Data is shown as mean (SD), as % of reference where applicable. None of the patients with stage I–II disease were on oral or inhaled 
corticosteroids. All patients with stage IV COPD had inhaled corticosteroid (below 1 mg). None of the patients were on N-acetylcysteine or 
vitamins. No one had previous asbestos exposure.
Table 2: Clinical characteristics of the patients in Western blot analyses
Non-smokers Smokers COPD st I–II COPD st IV p-value
Total (n) 8 9 9 6
Male/Female 3/4* 6/3 6/3 5/1
Age (years) 64 (12) 60 (7) 64 (9) 53 (6)
Pack years 0 36 (15) 37 (12) 32 (22) p < 0.0001
FEV1 (l) 2.9 (1.1) 3.0 (0.6) 2.0 (0.5) 0.5 (0.2) p < 0.0001
FEV1 (% of ref) 99 (21) 87 (15) 68 (14) 16 (7) p < 0.0001
FEV1/FVC (%) 88 (6) 82 (11) 73 (12) 35 (12) p < 0.0001
DCO (% of ref) 92 (20) 83 (8) 65 (14) 29 (8) p < 0.0001
DCO/VA (% of ref) 95 (19) 88 (8) 71 (17) 38 (10) p < 0.0001
Data is shown as mean (SD), as % of reference where applicable. *One healthy organ donor, background details missing. Three patients with stage 
II COPD and all patients with stage IV COPD had inhaled corticosteroid (below 1 mg). None of the patients were on N-acetylcysteine or vitamins. 
No one had previous asbestos exposure.Page 3 of 11
(page number not for citation purposes)
Respiratory Research 2006, 7:133 http://respiratory-research.com/content/7/1/133hoc comparisons were performed using two-tailed t tests.
Categorical data were compared using Fisher's exact test.
P-values less than 0.05 were considered statistically signif-
icant. Correlations to lung functions were analyzed with
the Spearman rank correlation test. The two independent
evaluations of immunohistochemical samples were com-
pared using Cohen's kappa statistics [27].
Results
The number of alveolar macrophages in tissue specimens
Since Grx1 is known to be highly expressed in alveolar
macrophages [18], a detailed analysis was conducted
where the number of alveolar macrophages per square
millimeter of tissue specimen was analyzed from all
groups of subjects i.e. non-smokers, smokers, stage I–II
COPD and stage IV COPD. These analyses showed an
increased number of macrophages especially, in the lung
tissue of smokers (p = 0.020) compared to non-smokers
(Fig 1).
Grx1 in healthy human lung and in different stages of 
COPD
Immunohistochemical studies on healthy lung and
COPD showed that Grx1 was mainly expressed in alveolar
macrophages (Fig 2A–D). Occasional faint positivity was
also detected in the bronchial epithelium in some cases
(Fig 2E). No immunoreactivity was seen in the negative
isotype control (Fig 2F). There were no statistically signif-
icant differences (p = 0.097) in the semiquantitative anal-
ysis of the immunohistochemical staining intensities
between any two groups of subjects. The evaluations by
two independent investigators showed moderate agree-
ment with each other according to Cohen's kappa statis-
tics (κ = 0.552).
When the cells were divided into two groups, either Grx1
positive or negative, the percentage of Grx1 positive mac-
rophages from the total macrophage population showed
a tendency to decrease during disease progression, being
lowest in stage IV COPD. This reduction was statistically
significant when compared to smokers (p = 0.021) (Fig 3).
There was no association between the pack years and the
percentage of positive macrophages. Interestingly, there
was a significant correlation between Grx1 positive mac-
rophages in the lung tissue specimens (containing lung
samples from all smokers and different stages of COPD)
and lung function parameters (FEV1, r = 0.45, p = 0.008;
FEV1%, r = 0.46, p = 0.007, FEV/FVC%, r = 0.55, p =
0.001) as shown in figure 4 (panels A-C).
Number of alveolar macrophagesFigur  1
Number of alveolar macrophages. The number of alve-
olar macrophages was assessed in healthy non-smokers (NS), 
smokers without COPD (S), stage I–II COPD and stage IV 
COPD (for patient characteristics see Table 1). The means of 
the numbers of alveolar macrophages per square millimeter 
are marked with horizontal lines. * Significantly increased 
when compared to non-smokers (p = 0.020).
Table 3: Clinical information of the patients included in induced sputum experiments
Non-smokers Smokers stable COPD COPD exa p-value
Total (n) 15 11 17 7
Male/Female 11/4 9/2 11/6 5/2
Age (years) 57 (6) 51 (6) 61 (8) 61 (7)
Pack years 0 31 (10) 40 (15) 35 (7) p < 0.0001
FEV1 (l) 3.6 (0.6) 3.9 (0.9) 2.2 (0.8) 1.1 (0.7) p < 0.0001
FEV1 (% of ref) 101 (10) 98 (11) 67 (20) 35 (20) p < 0.0001
FEV1/FVC (%) 81 (5) 81 (4) 66 (12) 47 (9) p < 0.0001
DCO (% of ref) 97 (9) 87 (12) 64 (16) 36 (22) p < 0.0001
DCO/VA (% of ref) 105 (10) 94 (9) 75 (21) 48 (28) p < 0.0001
Data is shown as mean (SD), as % of reference where applicable. None of the patients with stable disease were on oral or inhaled corticosteroids. 
The stable COPD represented patients with mild stage 0–I COPD and COPD exa group represented patients with COPD exacerbation as 
described. Oral corticosteroid and antibiotic had been started to all patients with COPD exacerbation within the last 48 hours. None of the 
patients were on N-acetylcysteine or vitamins.Page 4 of 11
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Immunohistochemical expression of Grx1 in lung specimensFigure 2
Immunohistochemical expression of Grx1 in lung specimens. Representative immunohistochemical expression of 
Grx1 in lung specimens from a healthy non-smoker (A), smoker without COPD (B), stage II COPD (C) and stage IV COPD 
(D). Grx1 was mainly expressed in alveolar macrophages in all cases. Occasional positivity was observed in the bronchial epi-
thelium as indicated by arrows (E). No immunoreactivity was seen in the negative isotype control (F). Dilutions used were 
1:3000 for goat anti-human Grx1 primary antibody and 1:300 for biotinylated rabbit anti-goat secondary antibody.
Respiratory Research 2006, 7:133 http://respiratory-research.com/content/7/1/133In agreement with this result the Western blot analysis of
lung homogenates (n = 32) showed that Grx1 levels were
decreased in COPD when compared to healthy smokers
(stage I–II p = 0.045 and stage IV p = 0.022) (Fig 5). In
these subjects, there was no statistically significant differ-
ence in the pack years between smokers and COPD (p =
0.818).
Unlike cytosolic Grx1, mitochondrial Grx2 could not be
detected by immunohistochemistry. In the Western blot
analysis Grx2 was hardly detectable and was only found in
cigarette smokers (data not shown).
Grx1 in the induced sputum supernatants
Grx1 could be detected by Western blot analysis in the
plasma samples from non-smokers, smokers and COPD
patients, but with high individual variability (see also Fig
6A) confirming previous findings on Grx1 in plasma
[19,20]. Since the intracellular localization of Grx1 in vac-
uoles [18,28] suggests possible export of Grx1 out of cells,
further studies were conducted using induced sputum
specimens from non-smokers (n = 15), smokers (n = 11)
and patients with COPD (n = 24). As expected, there was
a prominent Grx1 immunoreactivity in the cells found in
induced sputum, as analyzed by immunocytochemistry
and Western blot (Fig 6B). However, Grx1 could also be
detected from the induced sputum supernatants of
healthy controls, smokers, stable COPD and COPD dur-
ing exacerbation (Fig 6C). The Grx1 protein levels
increased in supernatants obtained from patients with
acute exacerbations when compared to non-smokers (p =
0.013), and also, to some extent, when compared to
smokers (p = 0.051) (Fig 6D). One explanation for the
extracellular Grx1 could be the disruption of the plasma
membrane, hence the specimens were analyzed for β-
actin and manganese superoxide dismutase (an antioxi-
dant enzyme previously found to be expressed in human
alveolar macrophages) [29]; the immunoreactivities for
both of these antigens were negative.
Correlation of tissue Grx1 with lung function parametersFigure 4
Correlation of tissue Grx1 with lung function param-
eters. Correlations between the percentage of Grx1 posi-
tive macrophages (of total macrophage population examined) 
and lung function parameters. The percentage of Grx1 posi-
tive macrophages was observed to significantly correlate with 
FEV1 (r = 0.45, p = 0.008), FEV1% (r = 0.46, p = 0.007) and 
FEV/FVC% (r = 0.55, p = 0.001).
Analysis of Grx1 positive macrophagesFigure 3
Analysis of Grx1 positive macrophages. The percentage 
(%) of Grx1 positive macrophages from the total number of 
alveolar macrophages in healthy non-smokers (NS), smokers 
without COPD (S), stage I–II COPD and stage IV COPD (for 
patient characteristics see Table 1). The means of the per-
centage of positive macrophages are marked with horizontal 
lines. * Significantly decreased when compared smokers (p = 
0.021).Page 6 of 11
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The present study suggests that Grx1 is a potential redox
modulatory protein regulating the homeostasis of glu-
tathionylated proteins and GSH not only in healthy lung
but also in cigarette smokers and in COPD patients. In
addition, the presence of Grx1 in the extracellular space
may play a role in the replenishment of glutathione in the
airways, especially during acute exacerbations where the
oxidant stress is increased.
One recent microarray study found no change in Grx1
mRNA levels in the bronchial epithelium of healthy
smokers compared to non-smokers [30]. In another study
on cultured bronchial epithelial cells, Grx was found to be
elevated by 10 fold during the first 10 hours of exposure
to cigarette smoke [31]. However, to date no human stud-
ies are available on the protein levels or the regulation of
Grxs in smokers' lung or in COPD patients. It is well
known that cigarette smoke can increase GSH levels in the
epithelial lining fluid and cause depletion of intracellular
free GSH [6,7]. It appears that after initial GSH depletion
intracellular GSH levels increase for reasons that are
unknown, one mechanism being increased GSH synthesis
[4,7,9]. Oxidative stress also causes accumulation of pro-
tein-GSH mixed disulfides [32]. Since the intracellular
concentration of cysteine-residues in proteins is higher
than the concentration of free GSH, the formation of pro-
tein-GSH mixed disulfides has the potential to serve as a
significant depository of GSH in living cells. Furthermore
it has been shown that in an oxidizing environment, a
major fraction of GSH is in fact present as mixed
disulfides with proteins [33]. Formation of these mixed
disulfides between GSH and proteins may serve both a
regulatory and an antioxidant function by protecting the
enzymes from irreversible oxidation that might lead to
enzyme inactivation. Once oxidative stress has been alle-
viated the protein-GSH mixed disulfides are efficiently
reduced by Grxs liberating free glutathione.
The present study suggests that Grx1 may be involved in
the regulation of glutathionylated protein levels and GSH
homeostasis in human lung (Fig 7). Immunohistochemi-
cal studies showed that Grx1 was mainly expressed in the
alveolar macrophages of non-smokers and smokers and at
different stages of COPD and that the level of Grx1
decreased according to the severity of the disease. These
conclusions are supported by Western blot analysis. Not
all macrophages in the sections were Grx1 positive, prob-
ably due to presence of various macrophage populations
and the age of these cells. Overall, these changes are
apparently related both to the total number macrophages
present in lung as well as to the differences in the expres-
sion levels of Grx in macrophages.
The present study confirmed that Grx1 can be detected
from the plasma, as shown previously [19,20], and more
importantly demonstrated that Grx1 could also be
detected from sputum, both from the cells and superna-
tants. The latter observation suggests that Grx1 may be
exported from alveolar macrophages to the extracellular
space (i.e. sputum extract). The levels of Grx1 in the spu-
tum supernatants were significantly higher in acute exac-
erbations of COPD than in the controls. This suggests that
extracellular Grx1 attempts to reduce GSH-mixed
disulfides during the oxidative stress in COPD to restore
active proteins and to increase the concentration of free
glutathione.
The assessment of functional Grx activity from the lung or
sputum specimens is difficult since the assays available
may not to be specific for Grx alone. In our recent paper
[34] we described a new method for measuring the deglu-
tathionylation activity in vitro, but also this assay is unsuit-
able for measuring the glutaredoxin activity in tissue or
Western blot analysis of Grx1 in lung homogenatesFigure 5
Western blot analysis of Grx1 in lung homogenates. 
Representative Western blot analysis of Grx1 expression in 
the specimens (n = 32) of healthy non-smokers and smokers 
without COPD and in different stages of COPD (for patient 
characteristics see Table 2). The total amount of protein was 
40 µg and the primary antibody dilution for human Grx1 was 
1:2500 in all cases. The means of the intensities measured are 
shown as columns with error bars representing SEM. * Signif-
icantly decreased when compared to smokers (p = 0.045). ** 
Significantly decreased when compared to smokers (p = 
0.022).Page 7 of 11
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thioredoxin family members showed deglutathionylation
activity, further suggesting that the current methods are
not specific for the assessment of Grx activity in vivo. Sup-
porting the findings in the present study, our recent obser-
vations showed that the activity of E. coli Grx1, which is
similar to human Grx1, is markedly reduced under condi-
tions mimicking oxidative stress [35].
Grx2 expression could not be detected reliably with the
methods used here. However, this does not rule out the
importance of Grx2 in the antioxidant defense of lung.
Grx2 is a mitochondrial protein [14,15] and therefore it
might have a role in the regulation of the mitochondrial
redox state and apoptotic events. Grx2 clearly needs fur-
ther investigation in order to better understand the role of
thiol oxidoreductases in the antioxidative defense mecha-
nisms in human lung and COPD progression.
The regulation of Grx1 is poorly understood, but recent
results of our laboratory and others have suggested minor
or non-significant Grx1 induction by oxidants [35,36]
and significant Grx1 downregulation by transforming
growth factor-beta (TGF-β) [18]. Grx1 is, however, only
one of the enzymes that regulate GSH homeostasis in
human lung. The rate limiting enzyme in GSH synthesis is
GCL and this enzyme has been shown to be transiently
induced by oxidative stress, cigarette smoke and COPD
[1,8,30,37] but decreased by TGF-β in vitro [38] and dur-
ing COPD progression in vivo [9,39]. The decrease of Grx1
in severe COPD/emphysema found here may in fact be
associated with a simultaneous downregulation of other
GSH associated enzymes in COPD thus further increasing
the oxidant burden in the lung. These regulatory pathways
clearly need to be studied in more detail.
Conclusion
In conclusion, Grx1 is a protein closely associated with
GSH and reduction of GSH-mixed disulfides. Grx1 is
located mainly in alveolar macrophages and the levels are
decreased according to severity of COPD. Grx1 can also be
detected from sputum supernatants, the levels being
higher in acute exacerbations of COPD than in healthy
controls. This increase in Grx1 levels may serve as an
Grx1 expression in induced sputum supernatants and plasma samplesFigur  6
Grx1 expression in induced sputum supernatants and plasma samples. Representative Western blot analysis of Grx1 
expression in the plasma (A) and induced sputum pellets (B) and supernatants (C) of healthy non-smokers (= NS), smokers (= 
S) and COPD patients (= C). The means of the intensities in the sputum supernatants were measured from total of 15 non-
smokers, 11 smokers, 17 stable COPD (stage 0–I) and 7 acute exacerbations (for patient characteristics see Table 3) and are 
shown as columns (D). The primary antibody dilution for human Grx1 was 1:2500 in all cases. Error bars represent SEM. * Sig-
nificantly increased when compared to non-smokers (p = 0.013).Page 8 of 11
(page number not for citation purposes)
Respiratory Research 2006, 7:133 http://respiratory-research.com/content/7/1/133attempt to restore the functional activity of glutathio-
nylated proteins and to increase the extracellular level of
free glutathione. Overall these findings suggest that Grx1
is involved in the regulation of both intracellular and
extracellular GSH homeostasis, and associated with the
decrease of the GSH dependent antioxidant defense in
severe COPD.
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Suggested role of Grxs in cigarette smoke induced oxidative stressFi ure 7
Suggested role of Grxs in cigarette smoke induced oxidative stress. The major function of Grx is the reduction of 
glutathionylated proteins back to their functional states both intracellularly and in the extracellular space with concomitant 
release of glutathione. ROS, reactive oxygen species; RNS, reactive nitrogen species; GSH, reduced glutathione; GSSG, oxi-
dized glutathione; GR, glutathione reductase; ELF, epithelial lining fluid.Page 9 of 11
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